ArticleRadiation oncology (London, England)2020
Radiotherapy in the treatment of aggressive fibromatosis: experience from a single institution.
Article in Radiation oncology (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Challenging aggressive surgical strategies in extraabdominal desmoid tumors: Is tumor volume the missing key?Acta orthopaedica et traumatologica turcica · 2026Article
- Intra-Oral Aggressive Fibromatosis: A Systematic Review of Case Reports and Case Series.Journal of clinical medicine · 2026Review
- Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis.Frontiers in oncology · 2025Article
- Navigating the Complexities of Radiation Injuries: Therapeutic Principles and Reconstructive Strategies.Journal of personalized medicine · 2024Review
- Secondary Osteosarcoma After Carbon-Ion Radiotherapy for Desmoid-Type Fibromatosis: A Case Report.Cancer reports (Hoboken, N.J.) · 2024Article
- ACR-ARS Practice Parameter for the Performance of Proton Beam Therapy.International journal of particle therapy · 2024Article
- Imaging manifestations of cervical aggressive fibromatosis: a case report and literature review.Frontiers in oncology · 2024Article
- Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis.Frontiers in oncology · 2024Article
- Update on Familial Adenomatous Polyposis-Associated Desmoid Tumors.Clinics in colon and rectal surgery · 2023Review
- Successful treatment with radiation therapy for desmoid-type fibromatosis with unilateral hydronephrosis: a case report.Journal of medical case reports · 2021Article
- Ruptured mesenteric desmoid-type fibromatosis without emergency surgery: A rare case report.International journal of surgery case reports · 2021Article
- Long-term follow up of a patient with a recurrent desmoid tumor that was successfully treated with proton beam therapy: A case report and literature review.Clinical and translational radiation oncology · 2021Article
- The Role of Radiation Therapy for Symptomatic Desmoid Tumors.Current treatment options in oncology · 2021Review
- Giant desmoid tumour of abdominal wall: resection and reconstruction by posterior component separation.BMJ case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDesmoid-type fibromatosis is a rare, potentially locally aggressive disease. Herein we present our experience in the treatment with radiotherapy. METHODS AND MATERIALS: In total 40 patients who received 44 treatments from 2009 to 2018 at the Heidelberg University Hospital with photons (N = 28) as well as protons (N = 15) and carbon ions (N = 1) were investigated. The median age at radiotherapy was 41 years [range 8-78]. Familial adenomatous polyposis (FAP) was confirmed for nine patients and 30 had a unifocal desmoid tumor. The localizations were abdominal wall, abdominopelvic cavity, thoracic wall, extremity, head and neck and trunk. The median prescribed dose was 54 Gy/ Gy (RBE) [range 39.6-66, IQR 50-60]. Eleven treatments were performed at the time of first diagnosis; 33 at the time of progression or recurrence. Post-operative radiotherapy was performed in 17 cases. The median planning target volume was 967 ml [84-4364 ml, IQR 447-1988]. Survival analysis was performed by the Kaplan-Meier Method.
resultsThe median follow-up time was 32 months [1-153]. At the end of the follow-up interval all patients but one were alive. The estimated local progression free survival of the treated lesion in 3 and 5 years was 76.4% and 63,8%, respectively. The progression-free survival in 3 and 5 years was 72.3 and 58.4% and the overall survival was 97.4 and 97.4%, respectively. In case of macroscopic tumor (N = 31) before radiotherapy a partial remission was observed in 12 cases (38.7%) and a complete remission in 4 cases (12.9%). Progression was observed in 13 (29.5%) cases, predominantly at the margin of the planning target volume (PTV, N = 5, 38,4%) followed by progression within the PTV (N = 4, 30.8%). In univariate analysis multifocal localization was associated with impaired progression-free survival (p = 0.013). One patient developed a grade V gastrointestinal bleeding, otherwise no acute toxicity >°III was observed. Late toxicity was depending on the localization of the desmoid tumor and was especially severe in patients with FAP and abdominopelvine desmoids including gastrointesinal fistula, perforation and abscess.
conclusionRadiotherapy in the treatment of desmoids can lead to long term control. Treatment of patients with abdominopelvine desmoids should be avoided, as the risk of higher-grade complications is substantial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.